Rapid Micro Biosystems (RPID) Free Cash Flow Growth (1y) (2021 - 2026)

Rapid Micro Biosystems (RPID) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Growth (1y) (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn -1.82%
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 226.77%
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn 0.77%
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn -51.69%
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn -109.40%
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 363.84%
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn -31.71%
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 133.09%
10 Rapid Micro Biosystems 89.73 Mn 80.30 Mn 371,000.00 -60.60%

Historic Data

Download Data
DateValue
Mar 31, 2026 -60.60%
Dec 31, 2025 77.77%
Sep 30, 2025 -12.81%
Jun 30, 2025 0.81%
Mar 31, 2025 41.75%
Dec 31, 2024 -21.08%
Sep 30, 2024 10.88%
Jun 30, 2024 -10.07%
Mar 31, 2024 7.65%
Dec 31, 2023 -67.44%
Sep 30, 2023 53.12%
Jun 30, 2023 33.44%
Mar 31, 2023 8.92%
Dec 31, 2022 60.34%
Sep 30, 2022 -2.98%
Jun 30, 2022 -14.50%
Mar 31, 2022 -66.37%
Dec 31, 2021 -153.39%
Sep 30, 2021 -137.66%